MA31663B1 - Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe - Google Patents
Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directeInfo
- Publication number
- MA31663B1 MA31663B1 MA32377A MA32377A MA31663B1 MA 31663 B1 MA31663 B1 MA 31663B1 MA 32377 A MA32377 A MA 32377A MA 32377 A MA32377 A MA 32377A MA 31663 B1 MA31663 B1 MA 31663B1
- Authority
- MA
- Morocco
- Prior art keywords
- reversible
- intervasive
- inhibitor
- oral
- dosage
- Prior art date
Links
- 239000002172 P2Y12 inhibitor Substances 0.000 title 1
- 230000002441 reversible effect Effects 0.000 title 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000006965 reversible inhibition Effects 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 229960000103 thrombolytic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91564907P | 2007-05-02 | 2007-05-02 | |
| US94792107P | 2007-07-03 | 2007-07-03 | |
| PCT/US2008/062518 WO2008137753A2 (en) | 2007-05-02 | 2008-05-02 | Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31663B1 true MA31663B1 (fr) | 2010-09-01 |
Family
ID=39587015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32377A MA31663B1 (fr) | 2007-05-02 | 2009-11-26 | Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20090048216A1 (OSRAM) |
| EP (1) | EP2079464A2 (OSRAM) |
| JP (1) | JP2010526101A (OSRAM) |
| KR (1) | KR20100029746A (OSRAM) |
| CN (1) | CN101795682A (OSRAM) |
| AU (1) | AU2008247483A1 (OSRAM) |
| BR (1) | BRPI0811476A2 (OSRAM) |
| CA (1) | CA2686203A1 (OSRAM) |
| CO (1) | CO6241104A2 (OSRAM) |
| EA (1) | EA200901473A1 (OSRAM) |
| EC (1) | ECSP099778A (OSRAM) |
| GT (1) | GT200900284A (OSRAM) |
| IL (1) | IL201834A0 (OSRAM) |
| MA (1) | MA31663B1 (OSRAM) |
| MX (1) | MX2009011843A (OSRAM) |
| TN (1) | TN2009000451A1 (OSRAM) |
| WO (1) | WO2008137753A2 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101423483B1 (ko) * | 2005-11-03 | 2014-07-28 | 포톨라 파마슈티컬스, 인코포레이티드 | 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법 |
| JP5390407B2 (ja) * | 2007-03-06 | 2014-01-15 | ノバルティス アーゲー | 炎症またはアレルギー症状の処置に適する二環式有機化合物 |
| JP2010526105A (ja) * | 2007-05-02 | 2010-07-29 | ポートラ ファーマシューティカルズ， インコーポレイテッド | ［４−（６−フルオロ−７−メチルアミノ−２，４−ジオキソ−１，４−ジヒドロ−２ｈ−キナゾリン−３−イル）−フェニル］−５−クロロ−チオフェン−２−イル−スルホニルウレア塩、異なる結晶形態、その医薬組成物 |
| US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| US9427448B2 (en) * | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| EP2384196B1 (en) * | 2008-12-30 | 2017-09-13 | Johansson, Pär | Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof |
| BR112012011298B1 (pt) | 2009-11-11 | 2021-12-14 | Chiesi Farmaceutici S.P.A. | Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos |
| US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| US8663661B2 (en) * | 2009-12-23 | 2014-03-04 | Ratiopharm Gmbh | Solid pharmaceutical dosage form of ticagrelor |
| WO2011088152A1 (en) | 2010-01-12 | 2011-07-21 | Portola Pharmaceuticals, Inc. | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
| WO2011137459A1 (en) * | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
| WO2012072743A1 (en) * | 2010-12-01 | 2012-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and kits for determining platelet susceptibility to activation in a patient |
| JP2013544271A (ja) * | 2010-12-03 | 2013-12-12 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法 |
| BR112019014567A2 (pt) | 2017-03-15 | 2020-02-18 | Idorsia Pharmaceuticals Ltd | Antagonista do receptor p2y12 ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de éster butílico do ácido |
| MA49452A (fr) | 2017-06-23 | 2021-05-05 | Chiesi Farm Spa | Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire |
| CN107462648B (zh) * | 2017-08-21 | 2019-09-27 | 盐城锦明药业有限公司 | 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| KR101423483B1 (ko) | 2005-11-03 | 2014-07-28 | 포톨라 파마슈티컬스, 인코포레이티드 | 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법 |
-
2008
- 2008-05-02 JP JP2010506688A patent/JP2010526101A/ja not_active Withdrawn
- 2008-05-02 BR BRPI0811476-5A2A patent/BRPI0811476A2/pt not_active IP Right Cessation
- 2008-05-02 CN CN200880023071A patent/CN101795682A/zh active Pending
- 2008-05-02 KR KR1020097025059A patent/KR20100029746A/ko not_active Withdrawn
- 2008-05-02 WO PCT/US2008/062518 patent/WO2008137753A2/en not_active Ceased
- 2008-05-02 CA CA002686203A patent/CA2686203A1/en not_active Abandoned
- 2008-05-02 US US12/114,630 patent/US20090048216A1/en not_active Abandoned
- 2008-05-02 AU AU2008247483A patent/AU2008247483A1/en not_active Abandoned
- 2008-05-02 EP EP08747561A patent/EP2079464A2/en not_active Withdrawn
- 2008-05-02 MX MX2009011843A patent/MX2009011843A/es not_active Application Discontinuation
- 2008-05-02 EA EA200901473A patent/EA200901473A1/ru unknown
-
2009
- 2009-10-29 IL IL201834A patent/IL201834A0/en unknown
- 2009-10-30 TN TNP2009000451A patent/TN2009000451A1/fr unknown
- 2009-10-30 GT GT200900284A patent/GT200900284A/es unknown
- 2009-11-26 MA MA32377A patent/MA31663B1/fr unknown
- 2009-12-02 EC EC2009009778A patent/ECSP099778A/es unknown
- 2009-12-02 CO CO09137697A patent/CO6241104A2/es not_active Application Discontinuation
-
2011
- 2011-09-16 US US13/235,305 patent/US20120009172A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008137753A3 (en) | 2009-02-12 |
| EA200901473A1 (ru) | 2010-06-30 |
| JP2010526101A (ja) | 2010-07-29 |
| MX2009011843A (es) | 2010-04-22 |
| EP2079464A2 (en) | 2009-07-22 |
| US20120009172A1 (en) | 2012-01-12 |
| IL201834A0 (en) | 2010-06-16 |
| GT200900284A (es) | 2012-01-31 |
| CN101795682A (zh) | 2010-08-04 |
| ECSP099778A (es) | 2010-01-29 |
| AU2008247483A1 (en) | 2008-11-13 |
| WO2008137753A2 (en) | 2008-11-13 |
| BRPI0811476A2 (pt) | 2014-11-04 |
| CA2686203A1 (en) | 2008-11-13 |
| US20090048216A1 (en) | 2009-02-19 |
| TN2009000451A1 (en) | 2011-03-31 |
| KR20100029746A (ko) | 2010-03-17 |
| CO6241104A2 (es) | 2011-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31663B1 (fr) | Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe | |
| EP1965823A4 (en) | METHOD FOR THE ADMINISTRATION OF HYPOGLYKEMIC AGENTS | |
| BRPI0407922A (pt) | derivados de isoquinolina e métodos de uso destes | |
| MA32070B1 (fr) | Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés | |
| MA32049B1 (fr) | Traitement du cancer avec des combinaisons d'inhibiteurs de topoisomerase et d'inhibiteurs de parp | |
| MA29857B1 (fr) | Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases | |
| IL177394A0 (en) | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | |
| MX395136B (es) | Composiciones farmaceuticas y metodos de administracion relacionados. | |
| MA35753B1 (fr) | Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2 | |
| MA33571B1 (fr) | Traitement de cellules tumorales astrocytaires avec des inhibiteurs de recepteurs d'endotheline | |
| NZ594589A (en) | 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents | |
| UA101601C2 (uk) | Інгібітори амідогідролази жирних кислот | |
| MA30765B1 (fr) | Derives innovants du thiophene | |
| EA200801551A1 (ru) | Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы | |
| EP1781257A4 (en) | PHARMACEUTICAL FORMULATIONS WITH MICROPARTICLES OR NANOPARTICLES OF AN AGENT | |
| MA31433B1 (fr) | Inhibiteurs de la p70 s6 kinase | |
| BR0114799A (pt) | Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos | |
| WO2007044085A3 (en) | Heteroaryl compounds and their uses as therapeutic agents | |
| MA34655B1 (fr) | Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse | |
| DK1819227T3 (da) | Farmaceutisk formulering af decitabin | |
| MY151295A (en) | Pyrimidyl indoline compound | |
| ATE554770T1 (de) | Therapeutisches mittel gegen entzündliche darmerkrankungen | |
| EA200201276A1 (ru) | Производные арилметиламина для использования в качестве ингибиторов триптазы | |
| WO2007046868A3 (en) | Thiazolidine derivatives and their uses as therapeutic agents | |
| EP2164518A4 (en) | FORMULATIONS FOR ORAL ADMINISTRATION OF THERAPEUTIC AGENTS AND RELEVANT PROCEDURES |